Related Experiment Video
Updated: May 4, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Immune activation throughout a boosted darunavir monotherapy simplification strategy.
O J BenMarzouk-Hidalgo1, A Torres-Cornejo, A Gutiérrez-Valencia
1Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain.
Ritonavir-boosted darunavir monotherapy is a safe HIV treatment simplification strategy. Viral blips do not impact immune activation, but virological failure increases it, especially with high baseline T-cell activation.
Area of Science:
- Immunology
- Virology
- HIV/AIDS Research
Background:
- Ritonavir-boosted darunavir monotherapy (mtDRV/rtv) is explored as a simplification strategy for HIV-1 infected patients.
- Understanding the impact of viral blips and virological failure (VF) on immune activation (IA) is crucial for long-term treatment success.
Purpose of the Study:
- To assess the evolution and impact of viral blips, intermittent low-level viraemia, and VF on immune activation profiles during mtDRV/rtv.
- To identify predictors of VF in patients on mtDRV/rtv.
Main Methods:
- Prospective cohort study (MonDAR) of 75 HIV-1 patients on mtDRV/rtv for 2 years.
- Assessed cellular IA (HLA-DR, CD38 on T-cell subsets) and systemic IA (sCD14, D-dimer).
- Classified patients into groups: continuous undetectable viraemia, blips, intermittent viraemia, and VF.
Main Results:
- Patients with sustained viral suppression showed decreased T-cell activation and IA markers.
- Transient low-level viraemia (blips, intermittent) had minimal impact on IA profiles.
- Virological failure was associated with significant increases in T-cell activation and systemic IA markers.
- High baseline HLA-DR(+)CD38(+)CD8(+) T-cells (>6.4%) independently predicted VF.
Conclusions:
- mtDRV/rtv is a safe simplification strategy when viral replication is controlled.
- Transient viraemia episodes do not negatively affect immune activation.
- Baseline T-cell activation levels are important considerations for switching to mtDRV/rtv to predict VF risk.
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Subviral Agents
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Retroviruses

